Point-of-Care Drug of Abuse Testing in the Opioid Epidemic

被引:15
|
作者
Li, Zhao [1 ]
Wang, Ping [1 ]
机构
[1] Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA
关键词
INVOLVED OVERDOSE DEATHS; TANDEM MASS-SPECTROMETRY; LATERAL FLOW ASSAY; CHRONIC PAIN; WEARABLE BIOSENSORS; UNITED-STATES; SUBSTANCE USE; DRIED URINE; SELF-REPORT; GC-MS;
D O I
10.5858/arpa.2020-0055-RA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-The United States is experiencing an opioid overdose epidemic. Point-of-care (POC) drug of abuse testing is a useful tool to combat the intensified opioid epidemic. Objectives.-To review commercially available POC drug of abuse testing involving opioids, to review opportunities and challenges for POC opioid testing and emerging testing methods in research literature, and finally to summarize unmet clinical needs and future development prospects. Data Sources.-The Google search engine was used to access information for commercial opioid POC devices and the Google Scholar search engine was used to access research literature published from 2000 to 2019 for opioid POC tests. Conclusions.-The opioid epidemic provides unprecedented opportunities for POC drug testing, with significant clinical needs. Compared with gold standard tests, limitations for commercially available opioid POC testing include lower analytical sensitivity, lower specificity, and cross-reactivity. In response to unmet clinical needs, novel methods have emerged in research literature, such as microfluidics and miniature mass spectrometry. Future prospects include the development of quantitative POC devices and smarter and real-time drug testing.
引用
收藏
页码:1325 / 1334
页数:10
相关论文
共 50 条
  • [1] Drug-of-Abuse Testing at the Point of Care
    Melanson, Stacy E. F.
    CLINICS IN LABORATORY MEDICINE, 2009, 29 (03) : 503 - +
  • [2] Point-of-care testing for drugs of abuse in an urban emergency department
    Mastrovitch, TA
    Bithoney, WG
    DeBari, VA
    Gold, NA
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2002, 32 (04): : 383 - 386
  • [3] The point of point-of-care testing
    Kassaye, Seble G.
    Katzenstein, David
    LANCET, 2011, 378 (9802): : 1532 - 1533
  • [4] Point-of-care testing in therapeutic drug monitoring of infliximab
    Sahinovic, I.
    Fric, V. Orsic
    Konjik, V.
    Pavela, J.
    Borzan, V.
    Seric, V.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I490 - I491
  • [5] Point-of-care testing in therapeutic drug monitoring of infliximab
    Sahinovic, I.
    Fric, V. Orsic
    Konjik, V.
    Pavela, J.
    Borzan, V.
    Seric, V.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I490 - I491
  • [6] HIV drug resistance testing - The quest for Point-of-Care
    Noguera-Julian, Marc
    EBIOMEDICINE, 2019, 50 : 11 - 12
  • [7] POINT-OF-CARE TESTING
    Newnam, Katherine M.
    ADVANCES IN NEONATAL CARE, 2018, 18 (02) : 84 - +
  • [8] Point-of-care testing
    Fiallos, MR
    Hanhan, UA
    Orlowski, JP
    PEDIATRIC CLINICS OF NORTH AMERICA, 2001, 48 (03) : 589 - +
  • [9] POINT-OF-CARE TESTING
    SANTRACH, PJ
    BURRITT, MF
    MAYO CLINIC PROCEEDINGS, 1995, 70 (05) : 493 - 494
  • [10] Point-of-care testing
    Jansen, RTP
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1999, 37 (10) : 991 - 991